

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-10 (cancelled).

Claim 11. (currently amended) A method of inhibiting recurrence of hepatocellular carcinoma, comprising administering ~~to a patient who has suffered from said carcinoma~~ an effective dose of a medicine containing menatetrenone to a patient who had hepatocellular carcinoma and was subjected to treatment of hepatocellular carcinoma in the past ~~as an active ingredient thereof, wherein said effective dose is administered after treatment of the hepatocellular carcinoma has occurred.~~

Claims 12-16 (cancelled).

Claim 17. (currently amended) The method of ~~any one of claims 10, claim 11, or 16,~~ wherein said effective dose of said medicine containing menatetrenone comprises the administration of generally 10 to 200 mg of menatetrenone per day to said patient.

Claim 18. (previously presented) The method of claim 17, wherein said effective dose of a medicine containing menatetrenone comprises the administration of generally 30 to 135 mg of menatetrenone per day to said patient.

Claim 19. (previously presented) The method of claim 18, wherein said effective dose of a medicine containing menatetrenone comprises the administration of 45 mg of menatetrenone per day to said patient.